Trial
NCT02140840
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Arkansas
Collaborators
—
Condition
Multiple Myeloma
Intervention
Trametinib
Why stopped
PI left institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-07